Clinical trials: Intravenous
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV) injection, and to evaluate efficacy on the basis of the changes seen in the cardiac biomarkers and continuous electrocardiography (ECG)…
- Trial name
- SUPPORT-1 (NCT00984802)
- Testing
- CMX-2043
- Where
- 5 sites in United States, India
- Volunteers
- 142 people
- Sponsor
- Ischemix, LLC
HIV Infections, HIV Seronegativity
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
- Trial name
- NCT00006327
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1
- Where
- Thailand
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- VaxGen
Invasive Aspergillosis
Micafungin Salvage Mono-therapy in Invasive Aspergillosis
To evaluate the efficacy and safety of micafungin in patients with proven invasive aspergillosis and who are refractory or intolerant to previous systemic antifungal therapy.
- Trial name
- NCT00376337
- Testing
- Micafungin, Systemic antifungal therapy
- Where
- 46 sites in Argentina, Belgium and 10 more
- Volunteers
- 17 people
- Sponsor
- Astellas Pharma Inc
Pruritus, Uremic Pruritus
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
The primary purpose of this study is to: Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week in patients who are undergoing hemodialysis.
- Trial name
- NCT02229929
- Testing
- Part A: CR845 0.5 mcg/kg, Part A: CR845 1.0 mcg/kg, Part A: CR845 2.5 mcg/kg
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- Cara Therapeutics, Inc.
Infiltration of Peripheral IV Therapy
ivWatch Model 400: Device Validation for Infiltrated Tissues
A single arm trial consisting of 70 adult volunteers to assess the safety and efficacy of the ivWatch Model 400 when observing infiltrated tissues at common sites for peripheral IV therapy.
- Trial name
- NCT02123745
- Testing
- The ivWatch Model 400
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- ivWatch, LLC
Neoplasms
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid…
- Trial name
- NCT01022853
- Testing
- BI 6727, BIBF 1120
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Immune Thrombocytopenic Purpura (ITP)
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic…
- Trial name
- NCT03866577
- Testing
- Biological: M254, Intravenous immunoglobulin (IVIg)
- Where
- 28 sites in United States, Belgium and 5 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Primary Immunodeficiency
Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml
Intravenous immunoglobulin (IVIG) is used for treatment of a heterogeneous group of immune related disorders both as immune-replacement and immune-modulating therapy.
- Trial name
- Nanogam (NCT01985373)
- Testing
- Intravenous immunoglobulin infusion
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Prothya Biosolutions
Solid Tumor
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: What does the study drug do to human body (Pharmacodynamics [='PD']) What does the body do to study drug (how processed in…
- Trial name
- NCT06086522
- Testing
- QN-302
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Qualigen Theraputics, Inc.
Stroke
Single and Repeat Doses of DMT in Healthy Subjects
This study aims to assess the safety and tolerability of single ascending, and fixed repeated doses of N,N-Dimethyltryptamine (DMT) in healthy subjects, when given by intravenous (IV) infusion.
- Trial name
- NCT05559931
- Testing
- N,N-Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Algernon Pharmaceuticals
Esophagitis, Reflux
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.
- Trial name
- NCT00175045
- Testing
- Lansoprazole
- Volunteers
- 68 people
- Sponsor
- Takeda
Healthy Volunteers
A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults
This study is to assess the plasma concentration-time profile of voriconazole in adults receiving 7-day intravenous treatment and 6.5-day oral treatment.
- Trial name
- NCT00855101
- Testing
- voriconazole
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cerebral Stroke, Ischemic Attack, Transient
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.
- Trial name
- NCT00119626
- Testing
- NXY-059
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Hypoplasminogenemia
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial
The clinical trial is no longer enrolling and is currently closing and Prometic will continue to provide Plasminogen (Human) under a treatment protocol to subjects in the United States (US) with hypoplasminogenemia requiring…
- Trial name
- NCT03642691
- Testing
- Ryplazim
- Where
- 3 sites in United States
- Sponsor
- Prometic Biotherapeutics, Inc.
Diabetes Mellitus, Type 2
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
- Trial name
- NCT01285518
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Leptomeningeal Carcinomatosis
A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent neoplastic meningitis.
- Trial name
- LMD (NCT00527410)
- Testing
- RTA 744
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Biogen
Healthy
Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects
This is a randomized, placebo controlled, single dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-E2 in healthy male subjects.
- Trial name
- GX-E2-P1 (NCT02291991)
- Testing
- GX-E2
- Where
- South Korea
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Alopecia Areata, Alopecia Totalis
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03532958
- Testing
- BNZ-1, Normal saline
- Sponsor
- Equillium
Advanced or Metastatic Solid Tumors
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting…
- Trial name
- Ulysse (NCT03316638)
- Testing
- W0101 - Cohort A1, W0101 - Cohort A2, W0101 - Expansion Phase
- Where
- 3 sites in France, Spain
- Volunteers
- 316 people
- Sponsor
- Pierre Fabre Medicament
Healthy Volunteers
A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.
The goal of this clinical trial is to assess initial safety/tolerability of multiple doses of drug NAV-240. It will also learn about the profile and immunogenicity of drug NAV-240.
- Trial name
- NCT06933043
- Testing
- NAV-240
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Navigator Medicines, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.